BioSpace News Archive

Paratek Pharmaceuticals, Inc. announced that the company will host a conference call and live audio webcast on Monday, Nov. 8, 2021 at 4:30 p.m.

X4 Pharmaceuticals, Inc., a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit patients with diseases of the immune system, announced that, on October 29, 2021, the Compensation Committee of X4’s Board of Directors issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan.

Neurocrine Biosciences, Inc. announced its financial results for the third quarter ended September 30, 2021.

Viracta Therapeutics, Inc., a precision oncology company targeting virus-associated malignancies, announced that company management is scheduled to present and host one-on-one meetings at the following upcoming investor conferences.

Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, announced that it will release third quarter 2021 financial results after the market closes on Monday, November 8, 2021.

Legend Biotech Corporation, a global, clinical-stage biotechnology company developing and manufacturing novel therapies, announced that the U.S. Food and Drug Administration has extended the Prescription Drug User Fee Act target date for ciltacabtagene autoleucel to February 28, 2022.

MEI Pharma, Inc., a late-stage pharmaceutical company focused on advancing new therapies for cancer, announced the grant of inducement stock options for an aggregate of 133,000 shares of the company’s common stock to two new employees.

Arrowhead Pharmaceuticals Inc. announced that it will host a webcast and conference call on November 22, 2021, at 4:30 p.m. ET to discuss its financial results for the fiscal year ended September 30, 2021.

Apollo Endosurgery, Inc., a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, announced financial results for the third quarter ended September 30, 2021 and recent corporate highlights.

LumiraDx a next-generation point of care diagnostics company announced that the intended use for its Food and Drug Administration Emergency Use Authorization authorized SARS-CoV-2 Antigen Test has been expanded to include screening of asymptomatic individuals.